News

Only small, nonsignificant improvements were observed in Unified Parkinson’s Disease Rating Scale motor scores, though the investigators did not report disease worsening with early treatment.

The professor of neurology at the NYU Langone Grossman School of Medicine outlined the confusion on whether deaths are related to COVID-19, a symptom associated, or previously unidentified underlying condition.

Researchers developed the biomarker in hopes of simplifying the recent MRPI 2.0 measurement for use in clinical practice.

The professor of clinical neurology at University of Miami and MT2020+ chair discussed the initiative’s effort to improve the global accessibility of mechanical thrombectomy.

The study authors noted that dementia prevention could become a compelling indication for older individuals receiving antihypertensive treatment.

The director of Translational Research and Clinical Trials Epilepsy at NYU Grossman School of Medicine discussed the need to improve education about nonmotor seizures.

The chief scientific officer of the Parkinson’s Foundation discussed how the PD GENEration initiative tackles 1 of the greatest unmet needs for patients with Parkinson disease.

Leigh Charvet, PhD, discusses the adoption and potential of validated digital and tele-based approaches for the treatment of multiple sclerosis.

The EXTEND and EPITHET trials selected patients by perfusion mismatch rather than the less sensitive noncontrast computed tomography, the findings providing reassurance of consistency for thrombolysis-induced reperfusion.

Veronica Hood, PhD, of the Dravet Syndrome Foundation, details the recently accepted ICD-10 codes for Dravet syndrome and what benefit they bring to patients.

The Mission Thrombectomy 2020+ group outlined a plan to increase the awareness, accessibility, and action for mechanical thrombectomy utilization for patients with stroke globally.

The drug joins Cerebryx as the second FDA-approved fosphenytoin for benzodiazepine-refractory status epilepticus.

New recommendations were developed for the use of rituximab, eculizumab, and methotrexate, as well as updates on previous recommendations for thymectomy.

The director of Translational Research and Clinical Trials Epilepsy at NYU Grossman School of Medicine discussed the groundwork done with the Human Epilepsy Project for a recent analysis.